No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination

Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter w...

Full description

Bibliographic Details
Main Authors: Anders Madsen, Linda Azimi, Sarah Tete, Fan Zhou, Florian Krammer, Rebecca Jane Cox, Åsne Jul-Larsen
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:Vaccine: X
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136219300300
id doaj-3ea0140a9ad04575a2056b0ba9bedf17
record_format Article
spelling doaj-3ea0140a9ad04575a2056b0ba9bedf172020-11-24T22:16:03ZengElsevierVaccine: X2590-13622019-08-012No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccinationAnders Madsen0Linda Azimi1Sarah Tete2Fan Zhou3Florian Krammer4Rebecca Jane Cox5Åsne Jul-Larsen6Influenza Centre, Department of Clinical Science, University of Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, Norway; K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, NorwayInfluenza Centre, Department of Clinical Science, University of Bergen, Norway; K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, NorwayDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USAInfluenza Centre, Department of Clinical Science, University of Bergen, Norway; K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, Norway; Department of Research and Development, Haukeland University Hospital, Bergen, Norway; Corresponding author at: Head of the Influenza Centre, Department of Clinical Science, University of Bergen, Laboratory Building, 5th Floor, Jonas Lies vei 87, N-5021 Bergen, Norway.Influenza Centre, Department of Clinical Science, University of Bergen, Norway; K.G. Jebsen Centre for Influenza Vaccine Research, Department of Clinical Science, University of Bergen, NorwayInfluenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009.We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC).The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza. Keywords: Healthcare worker, Antigenic seniority, AS03, Pandemic vaccinehttp://www.sciencedirect.com/science/article/pii/S2590136219300300
collection DOAJ
language English
format Article
sources DOAJ
author Anders Madsen
Linda Azimi
Sarah Tete
Fan Zhou
Florian Krammer
Rebecca Jane Cox
Åsne Jul-Larsen
spellingShingle Anders Madsen
Linda Azimi
Sarah Tete
Fan Zhou
Florian Krammer
Rebecca Jane Cox
Åsne Jul-Larsen
No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
Vaccine: X
author_facet Anders Madsen
Linda Azimi
Sarah Tete
Fan Zhou
Florian Krammer
Rebecca Jane Cox
Åsne Jul-Larsen
author_sort Anders Madsen
title No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_short No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_full No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_fullStr No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_full_unstemmed No evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
title_sort no evidence of antigenic seniority in hemagglutinin specific antibody responses after adjuvanted pandemic 2009 influenza vaccination
publisher Elsevier
series Vaccine: X
issn 2590-1362
publishDate 2019-08-01
description Influenza is a contagious respiratory illness caused by the influenza virus. The pandemic outbreak of influenza A H1N1 in 2009 (H1N1pdm09) gave us a unique opportunity to study humoral immune responses to a novel influenza vaccine strain. Here, we investigate how an individual’s previous encounter with different influenza subtypes influences the humoral response after pandemic vaccination in 2009.We retrospectively chose and grouped 80 vaccinated healthcare workers (HCWs) based on their year of birth into 4 groups, reflecting which influenza subtype they were likely first exposed to during childhood. Pre- and 21 days post- vaccination sera were analyzed. We investigated antibodies to the major surface protein hemagglutinin (HA), and specifically antibodies binding to the conserved stalk domain of the HA-protein. Serological assays were used to assess the quantity and functionality of the influenza-specific antibodies, including virus neutralization and activation of natural killer (NK) cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC).The AS03-adjuvanted H1N1pdm09 vaccine elicited robust antibody responses in all groups of HCWs. We found that the more antigenically experienced individuals had higher pre-vaccination antibody-levels towards the stalk domain of the HA. We also demonstrated that despite their inferior pre-vaccination antibody levels, the younger individuals reached similar antibody levels as the older birth-cohorts after pandemic vaccination. Our findings are important for understanding the effect of AS03 adjuvant on the antibody response in individuals exposed to different influenza viruses during their early childhood years, which is crucial for developing vaccine strategies against influenza. Keywords: Healthcare worker, Antigenic seniority, AS03, Pandemic vaccine
url http://www.sciencedirect.com/science/article/pii/S2590136219300300
work_keys_str_mv AT andersmadsen noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT lindaazimi noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT sarahtete noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT fanzhou noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT floriankrammer noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT rebeccajanecox noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
AT asnejullarsen noevidenceofantigenicseniorityinhemagglutininspecificantibodyresponsesafteradjuvantedpandemic2009influenzavaccination
_version_ 1725791556601905152